IN THE SPOTLIGHT

Medscape Onsite: Riding the Wave of NSCLC Updates From San Diego

Medscape Onsite: Riding the Wave of NSCLC Updates From San Diego

Advanced ALK-Rearranged NSCLC

Advanced ALK-Rearranged NSCLC

Oncology expert reveals the impact of biomarker testing on the outcomes of targeted therapies for cancer

Oncology expert reveals the impact of biomarker testing on the outcomes of targeted therapies for cancer

Nuvalent boosts offering to $500M following promising NSCLC results

Nuvalent boosts offering to $500M following promising NSCLC results

NSCLC Biomarker Testing: Multidisciplinary Decisions and Timely Testing Are Key

NSCLC Biomarker Testing: Multidisciplinary Decisions and Timely Testing Are Key

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer via concurrent integrin and MET signaling

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer via concurrent integrin and MET signaling

Role of Pulmonologists in Precision Medicine: Attitudes Towards Biomarker Testing for NSCLC

Role of Pulmonologists in Precision Medicine: Attitudes Towards Biomarker Testing for NSCLC

ALK-positive Non-Small Cell Lung Cancer Pipeline Drugs 2024 | Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others.

ALK-positive Non-Small Cell Lung Cancer Pipeline Drugs 2024 | Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others.

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024

Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer

Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer

'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC

'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

FDA approves Alecensa for certain patients with ALK-positive lung cancer

FDA approves Alecensa for certain patients with ALK-positive lung cancer

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review

Dr Mark Socinski on How Targeted Therapies Have Impacted Lung Cancer Outcomes

Dr Mark Socinski on How Targeted Therapies Have Impacted Lung Cancer Outcomes

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

Alectinib shows promise in early-stage ALK-positive non-small cell lung cancer

Alectinib shows promise in early-stage ALK-positive non-small cell lung cancer